February 27th Options Now Available For Abbott Laboratories (ABT)

Abbott Laboratories (ABT) is trading at $127.60 and Stock Options Channel highlights a $123 put (bid $1.93) and a $131 call (bid $2.11) expiring Feb 27. Selling the $123 put nets a $121.07 cost basis (before commissions), is ~4% out‑of‑the‑money and is assigned a 68% probability of expiring worthless, equating to a 1.57% cash return (11.45% annualized); selling a covered $131 call would produce a 4.32% total return if called away, with a 58% chance of expiring worthless and a 1.65% premium boost (12.07% annualized). Implied volatility for both contracts is ~25% versus a trailing 12‑month volatility of 22%, and the piece frames these figures as trade ideas rather than company fundamental news.

Analysis

Market structure: The options market is signaling modest income demand rather than directional distress — ABT’s 123 put yields a 1.57% one-period return (11.45% annualized) with a ~68% probability of expiring OTM; the 131 covered-call yields 4.32% to callaway (1.65% if OTM) with ~58% OTM odds. That benefits income-focused retail and systematic option sellers while slightly compressing implied downside protection costs for value buyers; primary value transfer is from implied-vol buyers to premium collectors, not from credit or currency markets.

Risk assessment: Tail risks include abrupt FDA/regulatory actions, a device recall or macro risk-off that spikes IV >35% and forces mark-to-market losses or assignment; low-probability assignment (if stock drops >4%) creates concentrated long exposure. Near-term (days–weeks) outcomes will be driven by IV and any biotech/regulatory headlines; medium-term (1–3 months) by results/seasonal flows; long-term fundamentals (>6 months) remain tied to ABT’s device/diagnostics revenue trends and buyback/dividend policy.

Trade implications: Primary actionable edge is asymmetric yield from option-selling: cash‑secured puts at 123 (target basis $121.07) and covered calls at 131 for existing holders are efficient uses of current 25% IV vs 22% realized spread. Use size limits (1–3% portfolio per trade), hard stops (close or roll if ABT < $118 or IV > 35%), and prefer monthly roll strategies to capture theta; consider collars if unwilling to accept assignment.

Contrarian angles: Consensus income chase understates assignment risk and the potential for short-term drawdowns from macro shocks — implied vol premium is modest, so the market isn’t pricing severe event risk. Mispricing exists only if you overestimate volatility — selling premium earns ~12% annualized if there is no adverse fundamental shock; unintended consequence: concentrated put-selling could force large purchases into a falling tape and compound losses.

Key Decisions for Investors

• Establish a cash‑secured put position: sell ABT Feb (≈30–60 day) 123 puts size = 1–3% notional of portfolio (one contract per 100 shares per $12k exposure). Target effective buy price $121.07; close/roll if ABT < $118 or IV spikes >35% or probability OTM falls below 50%.
• For existing ABT holders: implement a covered‑call sleeve — buy/hold up to 2% portfolio in ABT and sell Feb 131 calls to collect $2.11 premium; roll monthly if still bullish, take profits if called away above $131 (target total return ≥4.3% to expiry).
• If concerned about assignment/drawdown, construct a 1–3 month collar: buy ABT (or hold existing), buy a 120 put and sell a 131 call (calibrate strikes to net cost ≤0.5% of position). Exit/adjust collar if ABT > $135 or if put cost >2x average paid when IV >30%.
• Relative value: enter a small pair trade (3–6 month horizon) long ABT vs short MDT (dollar‑neutral, size 1–2% portfolio) to exploit ABT’s lower realized vol and diversified diagnostics exposure. Trim if ABT vs MDT total return gap exceeds +6% or if company‑specific regulatory news reverses trend.